A court in Zhejiang, China, dismissed the case filed by Huadong Medicine (SHE:000963) subsidiary Hangzhou Sino-American Huadong Pharmaceutical against three defendants for alleged patent infringement, according to a Monday filing with the Shenzhen bourse.
Huadong claimed that one of the defendants, Qinghai Zhufeng Cordyceps Raw Material, copied the listed company's raw material for its Bailin capsules and submitted fake documents, the filing said.
The company will file an appeal with China's Supreme People's Court, it said.
Shares fell 3% during the close of trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments